scispace - formally typeset
G

Giulia Ferrannini

Researcher at Karolinska Institutet

Publications -  44
Citations -  516

Giulia Ferrannini is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 23 publications receiving 323 citations. Previous affiliations of Giulia Ferrannini include Columbia University & University of Turin.

Papers
More filters
Journal ArticleDOI

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

Giulia Ferrannini, +5 more
- 01 Sep 2015 - 
TL;DR: Combining SGLT2 inhibition with caloric restriction is expected to be associated with major weight loss and chronic glycosuria elicits an adaptive increase in energy intake.
Journal ArticleDOI

Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease—A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V

Giulia Ferrannini, +13 more
- 20 Feb 2020 - 
TL;DR: Urgent action is required for both screening and management of patients with CAD and dysglycemia, in the expectation of a substantial reduction in risk of further cardiovascular events and in complications of diabetes, as well as longer life expectancy.
Journal ArticleDOI

Genetic backgrounds determine brown remodeling of white fat in rodents

Giulia Ferrannini, +7 more
- 01 Oct 2016 - 
TL;DR: This study provides new insights into the role of genetic variation in fat remodeling in susceptibility to metabolic diseases by comparing the response of C57BL/6J, 129/Sv and FVB/NJ mouse strains to cold.
Journal ArticleDOI

Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study

Giulia Ferrannini, +11 more
- 27 Jan 2020 - 
TL;DR: It is concluded that CAD severity and quality do not differ between participants with T2D and without diabetes, and renin, GDF15, and adiponectin are shared markers by T2d and CAD; several proteins are specifically associated with T1D or CAD; and in T3D, lower renin levels may protect against CAD.
Journal ArticleDOI

Use of Sodium‐Glucose Co‐transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry

Peter Moritz Becher, +20 more
- 02 Mar 2021 - 
TL;DR: In this paper, the authors investigated the association between SGLT2i use and outcomes in real-world heart failure patients with Type 2 diabetes mellitus and found that SGL2i was associated with a 30% lower risk of cardiovascular (CV) death/first HF hospitalisation (hazard ratio 0.70, 95% confidence interval 0.52-0.95).